NPCE Quote, Financials, Valuation and Earnings

Intelligent Bio Solutions, Inc. has a net margin of -12.78% compared to NeuroPace, Inc.'s net margin of -269.38%. NeuroPace, Inc.'s return on equity of -149.8% beat Intelligent Bio Solutions, Inc.'s return on equity of -255.54%.

NeuroPace, Inc. has a consensus price target of $19.25, signalling upside risk potential of 12.97%. On the other hand Intelligent Bio Solutions, Inc. has an analysts' consensus of -- which suggests that it could grow by 1134.57%. Given that Intelligent Bio Solutions, Inc. has higher upside potential than NeuroPace, Inc., analysts believe Intelligent Bio Solutions, Inc. is more attractive than NeuroPace, Inc..

NeuroPace, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intelligent Bio Solutions, Inc. has a beta of 4.455, suggesting its more volatile than the S&P 500 by 345.491%.

NeuroPace, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroPace, Inc. pays -- of its earnings as a dividend. Intelligent Bio Solutions, Inc. pays out -- of its earnings as a dividend.

NeuroPace, Inc. quarterly revenues are $27.4M, which are larger than Intelligent Bio Solutions, Inc. quarterly revenues of $1.1M. NeuroPace, Inc.'s net income of -$3.5M is lower than Intelligent Bio Solutions, Inc.'s net income of -$3M. Notably, NeuroPace, Inc.'s price-to-earnings ratio is -- while Intelligent Bio Solutions, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroPace, Inc. is 5.72x versus 8.78x for Intelligent Bio Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools, Inc. has a net margin of -12.78% compared to NeuroPace, Inc.'s net margin of -162.05%. NeuroPace, Inc.'s return on equity of -149.8% beat Standard BioTools, Inc.'s return on equity of -24.44%.

NeuroPace, Inc. has a consensus price target of $19.25, signalling upside risk potential of 12.97%. On the other hand Standard BioTools, Inc. has an analysts' consensus of $1.55 which suggests that it could fall by -3.73%. Given that NeuroPace, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe NeuroPace, Inc. is more attractive than Standard BioTools, Inc..

NeuroPace, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Standard BioTools, Inc. has a beta of 1.264, suggesting its more volatile than the S&P 500 by 26.42%.

NeuroPace, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroPace, Inc. pays -- of its earnings as a dividend. Standard BioTools, Inc. pays out -- of its earnings as a dividend.

NeuroPace, Inc. quarterly revenues are $27.4M, which are larger than Standard BioTools, Inc. quarterly revenues of $19.6M. NeuroPace, Inc.'s net income of -$3.5M is higher than Standard BioTools, Inc.'s net income of -$31.7M. Notably, NeuroPace, Inc.'s price-to-earnings ratio is -- while Standard BioTools, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroPace, Inc. is 5.72x versus 4.74x for Standard BioTools, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR, Inc. has a net margin of -12.78% compared to NeuroPace, Inc.'s net margin of -25.94%. NeuroPace, Inc.'s return on equity of -149.8% beat LENSAR, Inc.'s return on equity of -1013.45%.

NeuroPace, Inc. has a consensus price target of $19.25, signalling upside risk potential of 12.97%. On the other hand LENSAR, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 21.26%. Given that LENSAR, Inc. has higher upside potential than NeuroPace, Inc., analysts believe LENSAR, Inc. is more attractive than NeuroPace, Inc..

NeuroPace, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LENSAR, Inc. has a beta of 0.695, suggesting its less volatile than the S&P 500 by 30.495%.

NeuroPace, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroPace, Inc. pays -- of its earnings as a dividend. LENSAR, Inc. pays out -- of its earnings as a dividend.

NeuroPace, Inc. quarterly revenues are $27.4M, which are larger than LENSAR, Inc. quarterly revenues of $14.3M. NeuroPace, Inc.'s net income of -$3.5M is higher than LENSAR, Inc.'s net income of -$3.7M. Notably, NeuroPace, Inc.'s price-to-earnings ratio is -- while LENSAR, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroPace, Inc. is 5.72x versus 2.48x for LENSAR, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Movano, Inc. has a net margin of -12.78% compared to NeuroPace, Inc.'s net margin of -5036.25%. NeuroPace, Inc.'s return on equity of -149.8% beat Movano, Inc.'s return on equity of -410.28%.

NeuroPace, Inc. has a consensus price target of $19.25, signalling upside risk potential of 12.97%. On the other hand Movano, Inc. has an analysts' consensus of $30.00 which suggests that it could grow by 4204.16%. Given that Movano, Inc. has higher upside potential than NeuroPace, Inc., analysts believe Movano, Inc. is more attractive than NeuroPace, Inc..

NeuroPace, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Movano, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

NeuroPace, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Movano, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroPace, Inc. pays -- of its earnings as a dividend. Movano, Inc. pays out -- of its earnings as a dividend.

NeuroPace, Inc. quarterly revenues are $27.4M, which are larger than Movano, Inc. quarterly revenues of $80K. NeuroPace, Inc.'s net income of -$3.5M is higher than Movano, Inc.'s net income of -$4M. Notably, NeuroPace, Inc.'s price-to-earnings ratio is -- while Movano, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroPace, Inc. is 5.72x versus 10.55x for Movano, Inc.. Usually stocks with elevated PS ratios are considered overvalued.